Privi Speciality Chemicals Ltd Q3 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Published 3 Aug 2026 | Chemicals & Petrochemicals | Market Cap: ₹14.3K Cr
The company is very bullish about growth, aiming for a minimum of 20% revenue growth for FY 2025-26, with volume growth around 15%. The company is confident of maintaining a minimum 20% revenue growth for FY 25-26, backed by a healthy order book of 65-70% already secured.
From Privi Speciality Chemicals Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Price
₹3,480
Market Cap
₹14.3K Cr
P/E Ratio
40.7
How does Privi Speciality Chemicals Ltd rank in Chemicals & Petrochemicals?
Compare Privi Speciality Chemicals Ltd against every Chemicals & Petrochemicals company this quarter on revenue, margins and earnings-call signals.
Privi Speciality Chemicals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹722 Cr, net profit ₹94 Cr.
Full financials →📊 Revenue & Sales Performance
- →The company is very bullish about growth, aiming for a minimum of 20% revenue growth for FY 2025-26, with volume growth around 15%.
- →A healthy order booking position of 65-70% for calendar year 2025 supports this confidence.
- →Product mix improvements and internal efficiency enhancements contribute to margin sustainability and growth.
- →Expansion through capacity increases and debottlenecking will support volume growth over the next 1-2 years.
- →New product development, including high-value specialty products and new flagship products, will add to growth.
- →Geographical expansion into markets like India, Africa, South Asia, and China is expected to drive growth, with >20% growth anticipated from Indian and African markets.
- →The Givaudan JV is ramping up and on track, supporting future revenue increases.
- →Ongoing R&D and planned capacity expansions worth INR 250-300 crores over 15-18 months will facilitate this growth.
📈 Profitability & Margins
- →The company is confident of maintaining a minimum 20% revenue growth for FY 25-26, backed by a healthy order book of 65-70% already secured.
- →Operating margins are expected to be sustained at around 20-23%, supported by improved yields, process efficiencies, and a favorable product mix.
- →EBITDA margin for Q3 was around 23%, with expectations to maintain similar margins going forward.
- →Profit after tax grew significantly, with Q3 PAT at INR 44 crores vs INR 29 crores last year; 9-month PAT increased 92% YoY to INR 121 crores.
- →Volume growth expected to be around 15% corresponding to the revenue growth of ~20%.
- →Continuous capacity expansions, debottlenecking, and new products (including JV with Givaudan) to support future earnings growth.
- →New product launches and entry into new geographies like Africa and India are expected to contribute positively.
- →The company aims to capitalize on all opportunities dynamically to sustain growth and margins.
🏗️ Capital Expenditure Plans
- →Privi Specialty Chemicals plans a capex of INR 250-300 crores over the next 15-18 months for capacity expansion and debottlenecking of flagship products.
- →This capex includes increasing existing product capacities and setting up capacities for a few new products.
- →New products under development will form the next phase of expansion, for which Environmental Clearances (EC) and permissions have already been applied.
- →The capex will be funded through a mix of internal accruals and debt.
- →No immediate fundraising like QIP is planned; however, it may be considered in the future based on requirements.
- →The company is also exploring co-manufacturing arrangements with competitors, though details are confidential.
- →Continuous process development and greenfield projects (e.g., JV with Givaudan) are part of growth strategy.
- →Capacity enhancements and new product launches aim to support 20%+ revenue growth in coming years.
💰 Fundraising & Capital Structure
- →The company plans a capital expenditure (capex) of around INR 250-300 crores over the next 15 to 18 months for capacity expansion, including debottlenecking and new products.
- →This capex will be funded through a mix of internal accruals and debt.
- →The balance sheet is strong enough to support additional borrowing, and the immediate capex needs will be met through internal accruals and debt.
- →Fundraising through Qualified Institutional Placement (QIP) or equity may be considered in the future based on requirements, but there is no immediate plan.
- →The company will take a call on any potential fundraises at an opportune time, depending on the demand and market environment.
📋 Order Book & Pipeline
- →The company has a healthy order booking position with about 65% to 70% of orders already confirmed for calendar year 2025.
- →Around 70% of the business is contracted, primarily with large multinational F&F and FMCG companies, following calendar-year contracts.
- →The remaining 30% is mostly spot market sales and largely within the Indian market.
- →Management is confident about achieving revenue growth guided for FY25 and maintaining strong margins due to secured raw materials aligned with production volumes.
- →There is visibility and confidence for a good order book position for the next few quarters, supporting growth.
- →The company expects no major disruptions in the order book despite geopolitical uncertainties.
- →The current capacity expansion and debottlenecking exercises support volume growth for the next 1-2 years, aligning with the current order book.
Key Metrics
Frequently Asked Questions
What were Privi Speciality Chemicals Ltd Q3 FY25 results?
The company is very bullish about growth, aiming for a minimum of 20% revenue growth for FY 2025-26, with volume growth around 15%. The company is confident of maintaining a minimum 20% revenue growth for FY 25-26, backed by a healthy order book of 65-70% already secured.
What is Privi Speciality Chemicals Ltd share price analysis?
Privi Speciality Chemicals Ltd currently shows a neutral. The stock trades at a P/E of 40.7 with a market cap of ₹14,250 Cr. Investors should review the full earnings analysis for detailed insights.
Is Privi Speciality Chemicals Ltd planning capital expenditure?
Privi Specialty Chemicals plans a capex of INR 250-300 crores over the next 15-18 months for capacity expansion and debottlenecking of flagship products.
Keep Privi Speciality Chemicals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.